Sign in

CIK 0001637715 · <br>Emerging growth company

OnKure Therapeutics, Inc.

Sign in to watch
Ticker
OKUR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
472309515
Phone
(720) 307-2892
Business address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
Former names
Reneo Pharmaceuticals, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$1,157
in 2 filings

Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 35 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-01-27 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +130,000 130,000
2025-01-27 Leverone Jason A. Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +65,000 65,000
2025-01-27 Hartley Dylan Chief Scientific Officer Grant or award · Employee Stock Option (right to buy) +45,000 45,000
2025-01-27 Agresta Samuel Chief Medical Officer Grant or award · Employee Stock Option (right to buy) +45,000 45,000
2024-10-07 Leonard Braden Michael Former 10% owner of RPHM Other acquisition +345,739 345,739
2024-10-07 Leonard Braden Michael Former 10% owner of RPHM Other acquisition +102,076 102,076
2024-10-04 Saccomano Nicholas A President and CEO Grant or award +4,556 4,556
2024-10-04 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +2,359 2,359
2024-10-04 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +1,485 1,485
2024-10-04 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +16,898 16,898
2024-10-04 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +8,449 8,449
2024-10-04 Saccomano Nicholas A President and CEO Grant or award · Employee Stock Option (right to buy) +542,232 542,232
2024-10-04 Phillips Andrew John Director Grant or award · Stock Option (right to buy) +15,300 15,300
2024-10-04 Manke Isaac Director Grant or award · Stock Option (right to buy) +15,300 15,300
2024-10-04 Leverone Jason A. Chief Financial Officer Grant or award +16,331 16,331
2024-10-04 Leverone Jason A. Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +5,781 5,781
2024-10-04 Leverone Jason A. Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +5,322 5,322
2024-10-04 Leverone Jason A. Chief Financial Officer Grant or award · Employee Stock Option (right to buy) +130,611 130,611
2024-10-04 Jansen Valerie Malyvanh Director Grant or award · Stock Option (right to buy) +15,300 15,300
2024-10-04 Hartley Dylan Chief Scientific Officer Grant or award · Employee Stock Option (right to buy) +137,603 137,603

Page 5 of 8 · 154 trades